Phospho-Stat3 (Tyr705) (B12) rabbit mAb SureLight®488 conjugate

Select Your Size Price
100 Tests(1125) $299.00
10 Tests(1125S) $99.00

Need to make a custom order?

Contact us
Product Overview
Description Considered an oncogene, Stat3 is constitutively active in 70% of solid and hematological tumors, including leukemia, lymphoma, and multiple myeloma. The IL-6-Jak-Stat3 pathway can mediate cancer inflammation through both mutation of key regulatory genes and environmental stressors. Attempts at directly targeting Stat3 in cancer therapy have focused on the development of phosphopeptides and mimics that interact with the phospho-tyrosine-SH2 domain of Stat3 in an effort to destabilize active dimers and prevent DNA binding. Stat3 is primarily phosphorylated at Tyr705 upon activation of the Jak-Stat3 pathway. Secondary phosphorylation at Tyr727 at the C-terminus is thought to occur after Tyr705 phosphorylation. However, studies in melanoma have shown constitutive phosphorylation at Tyr727 that promotes survival of these cancerous cells.
Product Details
More Information
Applications Flow Cytometry
Clone Stat3Y705-B12
Format SureLight 488
Validated Reactivity Human, Mouse
Cross Reactivity Predicted to work with mouse, rat and other homologues.
Detection Anti-Rabbit IgG
Clonality Monoclonal
Immunogen A synthetic phospho-peptide corresponding to residues surrounding Tyr705 of human phospho Stat3
Formulation 1X PBS, 0.09% NaN3, 0.2% BSA
Isotype Rabbit IgG1k
Preparation Protein A+G
Recommended Usage For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.
Storage 2-8ºC
Pseudonyms Signal transducer and activator of transcription 3, Acute-phase response factor, APRF
Uniprot ID P40763
References Avalle L, Pensa S, Regis G, Novelli F, and Poli V. (2012) JAK-STAT. 1: 65-72.
Yu H, Pardoll D, and Jove R. (2009) Nature Review Cancer. 9: 798-809.
Sakaguchi M, Oka M, Iwasaki T, Fukami Y, and Nishigori C. (2012) Journal of Investigative Dermatology. 132: 1877-1885.
Cell Culture Products
Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNa IL4 and pervanadate (green) using Phospho-Stat3 (Tyr705) antibody Stat3Y705 B12-SureLight® 488 Cat. #1125.